Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Massachusetts General Hospital and Harvard Clinical Research Institute, Boston, MA, USA.
Int J Cardiol. 2018 Nov 15;271:324-330. doi: 10.1016/j.ijcard.2018.04.006.
Circulating concentrations of N-terminal fragment of the prohormone of brain natriuretic peptide (NT-proBNP) are influenced by age and common age-related comorbidities, such as renal dysfunction. Therefore, utility of NT-proBNP for prediction of prognosis in the aged has been questioned. We aimed to investigate the prognostic value of NT-proBNP across age classes in a cohort of patients with chronic systolic HF.
We enrolled 2364 consecutive outpatients with HF and left ventricular ejection fraction ≤50%. Patients were classified according to age quartiles, and a very elderly subgroup was identified, aged ≥85 years. After baseline assessment (including NT-proBNP testing), patients were followed-up for the composite of cardiovascular death, heart transplantation or ventricular assistance device implantation (primary outcome) and for all-cause death (secondary outcome). Patients in the fourth quartile (Q4, age ≥ 77 years, n = 638) and in the very elderly subgroup (age ≥ 85 years, n = 153), had higher NT-proBNP (p < .001 vs Q1). NT-proBNP was independently associated with primary and secondary outcome at 1- and 5-years follow-up in the whole population, as well as in Q4 and in the very elderly subgroup (all p < .05). Compared to the whole population, Q4 and very elderly had higher NT-proBNP cut-off for prediction of 1-year primary (4188 and 9729 ng/l, respectively vs 3710 ng/l) and secondary outcome (4296 and 7634 ng/l, respectively vs 3056 ng/l).
NT-proBNP predicts mortality in elderly and very elderly patients with chronic systolic HF, both at mid- and long-term follow-up. Higher NT-proBNP prognostic cut-off should be considered in the aged HF population.
脑钠肽前体 N 端片段(NT-proBNP)的循环浓度受年龄和常见的与年龄相关的合并症(如肾功能不全)的影响。因此,NT-proBNP 用于预测老年人预后的效用受到了质疑。我们旨在研究 NT-proBNP 在慢性收缩性心力衰竭患者的年龄组中的预后价值。
我们纳入了 2364 例连续的心力衰竭和左心室射血分数≤50%的门诊患者。根据年龄四分位数对患者进行分类,并确定了一个非常高龄的亚组,年龄≥85 岁。在基线评估(包括 NT-proBNP 检测)后,对患者进行了心血管死亡、心脏移植或心室辅助装置植入(主要终点)和全因死亡(次要终点)的复合终点随访。第四四分位数(Q4,年龄≥77 岁,n=638)和非常高龄亚组(年龄≥85 岁,n=153)的患者的 NT-proBNP 水平更高(p<0.001 与 Q1 相比)。在整个研究人群中,以及在 Q4 和非常高龄亚组中,NT-proBNP 在 1 年和 5 年随访时与主要和次要终点独立相关(均 p<0.05)。与整个研究人群相比,Q4 和非常高龄亚组预测 1 年主要终点(分别为 4188 和 9729ng/l,与 3710ng/l 相比)和次要终点(分别为 4296 和 7634ng/l,与 3056ng/l 相比)的 NT-proBNP 截断值更高。
NT-proBNP 可预测慢性收缩性心力衰竭老年和非常高龄患者的死亡率,无论是在中期还是长期随访中。在老年心力衰竭患者中应考虑更高的 NT-proBNP 预后截断值。